Herophilus Company Profile

Background

Herophilus, established in 2017 and formerly known as System1 Biosciences, is a San Francisco-based biotechnology firm dedicated to developing neurotherapeutics aimed at curing complex brain diseases. The company's mission is to leverage advanced technologies to address the challenges in treating neurological and psychiatric disorders. By integrating brain organoid science, systems neuroscience, robotic automation, and machine learning, Herophilus seeks to revolutionize drug discovery for conditions such as epilepsy, autism, and schizophrenia.

Key Strategic Focus

Herophilus's strategic focus centers on:

Human Brain Models: Utilizing patient-derived stem cells to create brain organoids that replicate human brain activity, capturing genetic and disease-specific biology absent in traditional animal models.

Automation and Scaled Biology: Implementing robotic automation to culture and assay thousands of high-quality, reproducible brain organoids, enabling extensive biological data collection.

Machine Learning and Advanced Analytics: Applying data analytics and machine learning to integrate large-scale phenotypic datasets, creating comprehensive systems biology descriptions of brain diseases.

Financials and Funding

Herophilus has undergone several funding rounds:

Seed Round (March 2017): Raised $100,000.

Series A2 (April 2017): Secured $5 million.

Series A1 (September 2018): Amount undisclosed.

Series 1 (December 2020): Amount undisclosed.

Notable investors include 515 Ventures, Alexandria Venture Investments, Asseily Ventures, Boom Capital Ventures, and CRV.

Pipeline Development

Herophilus's pipeline includes:

Rett Syndrome: Developing treatments for this rare neurological disorder.

Schizophrenia: Collaborated with Cerevel Therapeutics to evaluate neuroimmune modulating therapeutic strategies, utilizing proprietary neuroimmune patient-derived brain organoids.

Alzheimer’s Disease: Engaged in discovery projects targeting Alzheimer's, leveraging advanced brain organoid models.

Technological Platform and Innovation

Herophilus's proprietary technologies include:

Orchard™: A protocol library for reprogramming and genetically engineering organoid-optimized stem cell lines, providing access to a diverse neurological disease patient stem cell biobank.

Orchestra™: A hybrid-cloud enterprise-scale software system for instrument and automation control, experiment tracking, data management, high-performance microscopy imaging, and machine learning pipeline development.

OrCA™: A modular organoid culture and assay system comprising function-specific workcells and optimized biology protocols for consistent organoid culture and high-throughput phenotypic assays.

Leadership Team

Saul Kato, Ph.D.: Co-Founder and Chief Executive Officer. Dr. Kato has a background in neuroscience and has been instrumental in integrating advanced technologies into Herophilus's drug discovery processes.

Sharath Hegde, Ph.D.: Chief Scientific Officer. Dr. Hegde brings over 30 years of experience in drug discovery and clinical development, previously serving as CSO at Recursion Pharmaceuticals and SVP at Theravance Biopharma.

Scott Saywell: Chief Business Officer. With over 25 years in the biotech industry, Mr. Saywell has held roles such as VP of Corporate Development and Strategy at Theravance Biopharma.

Kenneth S. Kosik, M.D.: Scientific Advisory Board Member. Dr. Kosik is a leading expert on Alzheimer's disease, contributing significantly to the understanding of Tau protein and synaptic plasticity.

Leadership Changes

Sharath Hegde, Ph.D.: Appointed as Chief Scientific Officer in May 2021.

Scott Saywell: Joined as Chief Business Officer in March 2022.

Kenneth S. Kosik, M.D.: Added to the Scientific Advisory Board in December 2021.

Competitor Profile

Market Insights and Dynamics

The neurotherapeutics market is characterized by significant unmet needs in treating complex brain diseases. Advances in human brain models, automation, and machine learning are driving innovation, with companies focusing on developing more effective treatments for neurological and psychiatric disorders.

Competitor Analysis

SUN bioscience: A biotech company engineering industry-standard organoids, focusing on scalable and reproducible organoid production.

Finch Therapeutics: Develops novel microbiome therapeutics, leveraging human-derived bacterial strains to address various diseases.

BioSymetrics: Integrates clinical and experimental data using machine learning to translate human disease biology into precision medicines.

Meliora Therapeutics: Develops precision oncology drugs using machine learning to identify novel therapeutic targets.

Strategic Collaborations and Partnerships

Cerevel Therapeutics: In December 2021, Herophilus partnered with Cerevel to evaluate neuroimmune modulating therapeutic strategies for schizophrenia, utilizing advanced brain organoid models.

Genentech: In September 2023, Genentech acquired Herophilus's proprietary high-throughput human organoid-based drug discovery platform, including Orchard™, Orchestra™, and OrCA™ technologies. Herophilus continues to advance its neurotherapeutic research programs.

Operational Insights

Herophilus's integration of human brain organoid models, automation, and machine learning positions it uniquely in the neurotherapeutics landscape. This approach enhances the relevance and scalability of drug discovery processes, offering a competitive advantage over traditional methods.

Strategic Opportunities and Future Directions

Post the acquisition of its discovery platform by Genentech, Herophilus is poised to focus on advancing its neurotherapeutic research programs. The company's strengths in innovative technologies and strategic collaborations position it to make significant contributions to the treatment of complex brain diseases.